# Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT00545311** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 40 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** NVA237
- **DRUG:** NVA237
- **DRUG:** NVA237
- **DRUG:** NVA237
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00545311
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545311, "Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00545311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*